144221
NM_001315507.1
NM_001315508.1
NM_006197.3
XM_006716336.3
XM_006716340.3
XM_006716349.3
XM_011544528.2
XM_011544529.2
XM_011544530.2
XM_011544532.2
XM_011544533.2
XM_011544534.2
XM_011544535.2
XM_011544540.2
XM_017013472.1
XM_017013473.1
XM_017013474.1
XM_017013475.1
XM_017013476.1
XM_017013477.1
XM_017013478.1
XM_017013479.1
XM_017013480.1
XM_017013481.1
XM_017013482.1
XM_017013483.1
XM_017013484.1
XM_017013485.1
XM_017013486.1
XM_017013487.1
XM_017013488.1
XM_017013489.1
XM_017013490.1
XM_017013491.1
XM_017013492.1
XM_017013493.1
XM_017013494.1
XM_017013495.1
XM_017013496.1
XM_017013497.1
XM_017013498.1
XM_017013499.1
XM_017013500.1
XM_017013501.1
XM_017013502.1
XM_017013503.1
XM_017013504.1
XM_017013505.1
XM_017013506.1
XM_017013507.1
XM_017013508.1
26%(+/-7% mRNA remaining)(HeLa cell line) [TaqMan® Assay ID: Hs00196390_m1]
HeLa cells were reverse transfected with 30 nM gene-specific siRNA or 30 nM Silencer® Negative Control #1 siRNA, using siPORT NeoFX Transfection Agent. 48 hours post-transfection, RNA was isolated, and then two-step qRT-PCR was performed using an appropriate TaqMan® Gene Expression Assay. 18S rRNA was used as an endogenous control. Validation results are expressed as average percent mRNA remaining, relative to Negative Control siRNA-treated samples, along with the standard deviation of multiple independent experiments.